You have 0 items in your cart
Anyone reading early research papers, clinical trial records or scientific discussions about Retatrutide may encounter another name:
LY3437943.
So what exactly is LY3437943, and how is it related to Retatrutide?
The simple answer is:
LY3437943 is the development code used for the investigational compound now widely known as Retatrutide.
The two names do not describe separate peptides.
They refer to the same investigational molecule at different stages and within different contexts of its development.
Is LY3437943 Retatrutide?
Yes.
LY3437943 and Retatrutide refer to the same investigational compound.
Retatrutide was developed by Eli Lilly and Company as a peptide with agonist activity at three metabolic receptors:
- GIP receptor
- GLP-1 receptor
- glucagon receptor
Because it activates three receptor systems, Retatrutide is commonly described as a triple receptor agonist.
Earlier scientific literature may refer to the molecule primarily as LY3437943.
As development progressed, the name Retatrutide became much more widely used.
What Does LY3437943 Mean?
LY3437943 is a development identifier.
Pharmaceutical research programmes routinely use internal codes to identify investigational compounds during discovery and clinical development.
These codes allow researchers to identify a specific molecule before—or alongside—the adoption of a generic drug name.
In this case:
LY3437943 → Retatrutide
The identifier is therefore particularly useful when searching older scientific literature.
What Does the “LY” in LY3437943 Mean?
The LY prefix is associated with compounds originating from Eli Lilly’s research and development programmes.
Similar development identifiers can be found throughout pharmaceutical research.
They are useful because a compound may pass through several stages of research before its generic name becomes widely recognised.
The numerical portion distinguishes the particular investigational compound within the development system.
It should not be interpreted as describing a dose, peptide length or receptor profile.
Is LY3437943 a Different Version of Retatrutide?
No.
LY3437943 should not be interpreted as a separate version, strength or formulation of Retatrutide.
It is a research identifier for the compound.
This distinction matters because scientific databases and publications may use different terminology depending on when the research was published.
Someone searching for Retatrutide research may therefore encounter both:
Retatrutide
and
LY3437943
Understanding that these names refer to the same investigational molecule makes the scientific literature easier to navigate.
Why Do Research Compounds Have Code Names?
Developing a new molecule is a long process.
A potential compound may be identified and investigated well before it receives the generic name by which it eventually becomes widely known.
Development codes provide researchers with consistent identifiers throughout this process.
They can appear in:
- scientific publications
- clinical trial registrations
- conference presentations
- pharmacology research
- regulatory documentation
- early-stage development reports
This is why understanding research identifiers can be important when reviewing scientific evidence.
Searching only the later generic name may not always reveal every relevant early publication.
Why Did LY3437943 Become Known as Retatrutide?
As an investigational compound advances through development, a standardised non-proprietary name can become established.
Retatrutide became the recognised generic name associated with LY3437943.
The transition from a development code to a generic name does not mean the original compound has suddenly been replaced.
Instead, it reflects a change in how the molecule is identified.
Researchers may still use LY3437943 when discussing earlier experiments or publications.
What Type of Compound Is LY3437943?
LY3437943, or Retatrutide, is an engineered peptide investigated as a GIP/GLP-1/glucagon receptor agonist.
This receptor profile is what makes the compound particularly notable.
Rather than targeting one metabolic receptor, it has agonist activity across three.
The receptors are:
GIP receptor
GIP stands for glucose-dependent insulinotropic polypeptide.
GIP is an incretin hormone involved in the physiological response to nutrient intake.
GLP-1 receptor
GLP-1 stands for glucagon-like peptide-1.
GLP-1 receptor signalling has been extensively studied in relation to metabolic regulation, nutrient responses and appetite-related pathways.
Glucagon receptor
Glucagon signalling contributes to hepatic metabolism, glucose regulation, nutrient availability and broader energy metabolism.
The inclusion of glucagon receptor agonism is particularly important because it differentiates Retatrutide from dual GIP/GLP-1 receptor agonists.
Is LY3437943 a Triple Agonist?
Yes.
LY3437943 is described as a triple agonist because Retatrutide has agonist activity at three receptor systems:
GIP + GLP-1 + glucagon
This is also why simply describing Retatrutide as a “GLP-1” does not capture its complete mechanism.
GLP-1 receptor agonism represents only one part of its receptor profile.
Is LY3437943 the Same as Tirzepatide?
No.
LY3437943/Retatrutide and Tirzepatide are different molecules.
Tirzepatide primarily activates:
GIP + GLP-1 receptors
Retatrutide activates:
GIP + GLP-1 + glucagon receptors
The additional glucagon receptor activity is one of the major mechanistic distinctions between the two.
Is LY3437943 the Same as Semaglutide?
No.
Semaglutide primarily acts as a GLP-1 receptor agonist.
LY3437943/Retatrutide has activity across three receptor systems.
Although both involve GLP-1 receptor signalling, their overall receptor profiles are therefore different.
Why Is LY3437943 Important When Searching for Retatrutide Research?
This is where knowing the development code becomes genuinely useful.
Scientific terminology changes as compounds progress through development.
Older publications may have been written before “Retatrutide” became the commonly recognised name.
Searching scientific databases for both:
Retatrutide
and
LY3437943
can therefore help researchers identify literature associated with different stages of the compound’s development.
The same principle applies to many investigational molecules.
Knowing historical research identifiers can make literature searches more comprehensive.
Does LY3437943 Mean a Particular Retatrutide Dose?
No.
The numbers in LY3437943 do not represent a dose.
They should not be interpreted as milligrams, concentration, molecular weight or a recommended amount.
LY3437943 is simply the compound’s development identifier.
Is LY3437943 a Brand Name?
No.
LY3437943 is a development code, not a commercial brand name.
Retatrutide is the non-proprietary name associated with the investigational compound.
These distinctions are useful when interpreting scientific papers, clinical trial records and other research material.
Frequently Asked Questions
What is LY3437943?
LY3437943 is the development code associated with Retatrutide, an investigational GIP/GLP-1/glucagon triple receptor agonist.
Is LY3437943 the same as Retatrutide?
Yes. LY3437943 and Retatrutide refer to the same investigational compound.
Who developed LY3437943?
LY3437943/Retatrutide was developed by Eli Lilly and Company.
What does LY3437943 stand for?
It is a pharmaceutical development identifier. The LY prefix is associated with Eli Lilly research compounds, while the number identifies the particular development compound.
Is LY3437943 a GLP-1?
It has GLP-1 receptor agonist activity, but it also activates GIP and glucagon receptors. It is therefore more accurately described as a triple receptor agonist.
Is LY3437943 Tirzepatide?
No. Tirzepatide and LY3437943/Retatrutide are distinct compounds with different receptor profiles.
Why do some studies call Retatrutide LY3437943?
Earlier research may use the development code that identified the molecule during pharmaceutical development.
Does LY3437943 refer to a dose?
No. The number is part of the research identifier and does not indicate dosage or concentration.
The Key Point
The relationship between the two names is straightforward:
LY3437943 = Retatrutide
LY3437943 is the development identifier, while Retatrutide is the name by which the investigational compound has become widely recognised.
Knowing both names is particularly useful when navigating scientific literature because earlier research may use the development code.
It also provides an interesting example of how terminology evolves during pharmaceutical research—from an internal compound identifier to a widely recognised scientific name.